Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
暂无分享,去创建一个
M. Cazzola | C. Pascutto | M. Paulli | G. Croci | L. Arcaini | M. Varettoni | R. Riboni | S. Rattotti | M. Gotti | E. Orlandi | S. Zibellini | E. Boveri | A. Corso | S. Mangiacavalli | M. L. Guerrera | L. Morello | M. Bonfichi | V. Fiaccadori
[1] M. Gertz. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management , 2013, American journal of hematology.
[2] L. Staudt,et al. MYD88 L265P somatic mutation in IgM MGUS. , 2012, The New England journal of medicine.
[3] N. Harris,et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.
[4] D. Cappellen,et al. MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. , 2012, The Journal of investigative dermatology.
[5] T. Therneau,et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. , 2012, Blood.
[6] M. Gertz,et al. Hodgkin lymphoma: 2012 update on diagnosis, risk‐stratification, and management , 2012, American journal of hematology.
[7] L. de Leval,et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas , 2012, Haematologica.
[8] R. Foà,et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. , 2012, Blood.
[9] L. Pasqualucci,et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.
[10] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[11] A. Sivachenko,et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.
[12] S. Pileri,et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. , 2011, Blood.
[13] R. Warnke,et al. Splenic B‐Cell Marginal Zone Lymphoma , 2011 .
[14] R. Siebert,et al. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma , 2011, Acta Neuropathologica.
[15] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[16] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[17] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[18] Joseph M. Connors,et al. Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.
[19] C. Pascutto,et al. Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. , 2011, Clinical lymphoma, myeloma & leukemia.
[20] R. Pfeiffer,et al. Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. , 2010, Blood.
[21] J. Keats,et al. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. , 2010, Blood.
[22] C. Pascutto,et al. Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. , 2009, Blood cells, molecules & diseases.
[23] T. Therneau,et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. , 2009, Clinical lymphoma & myeloma.
[24] M. Björkholm,et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. , 2008, Blood.
[25] Antony V. Cox,et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing , 2008, Nature Genetics.
[26] A. Rossi,et al. A multicenter retrospective clinical study of CD5/CD10‐negative chronic B cell leukemias , 2008, American journal of hematology.
[27] A. Salar,et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria , 2008, Leukemia.
[28] C. Morton,et al. Characterization of familial Waldenstrom's Macroglobulinemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] F. Ajchenbaum‐Cymbalista,et al. Deciphering leukemic B-cell chronic lymphoproliferative disorders , 2006, Leukemia & lymphoma.
[30] A. Rossi,et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Órfão,et al. Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma. , 2005, Clinical lymphoma.
[32] L. Cavanna,et al. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders , 2004, Leukemia.
[33] M. Dimopoulos,et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[34] Mario Cazzola,et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. , 2012, Blood.
[35] T. Therneau,et al. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM). , 2011, Clinical lymphoma, myeloma & leukemia.
[36] I. Ghobrial,et al. Waldenström macroglobulinemia , 2004, Current treatment options in oncology.